diclofenac sodium topical patch (HP-5000) / Hisamitsu - LARVOL DELTA

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee (clinicaltrials.gov) - P3 | N=370 | Completed | Sponsor: Noven Pharmaceuticals, Inc. | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Jul 2022

Trial completion • Trial completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Irritation and Sensitization Study of HP-5000 Topical System (clinicaltrials.gov) - P1 | N=200 | Completed | Sponsor: Noven Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Irritation and Sensitization Study of HP-5000 Topical System (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: Noven Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Osteoarthritis • Pain • Rheumatology

Irritation and Sensitization Study of HP-5000 Topical System (clinicaltrials.gov) - P1; N=200; Recruiting; Sponsor: Noven Pharmaceuticals, Inc.; Trial completion date: Sep 2021 ➔ May 2022; Trial primary completion date: Aug 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Irritation and Sensitization Study of HP-5000 Topical System (clinicaltrials.gov) - P1; N=200; Recruiting; Sponsor: Noven Pharmaceuticals, Inc.

Clinical • New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee (clinicaltrials.gov) - P3; N=352; Recruiting; Sponsor: Noven Pharmaceuticals, Inc.

Clinical • New P3 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis (clinicaltrials.gov) - P2; N=289; Completed; Sponsor: Noven Pharmaceuticals, Inc.; Recruiting ➔ Completed

Trial completion

Hisashi honey percutaneous absorption-type anti-inflammatory analgesic effect in good [Google Translation] (Medical News) - "Hisamitsu Pharmaceutical Co., Ltd. announced that the transdermal anti-inflammatory drug 'HP-5000' (diclofenac sodium) has been shown to be effective in a phase 2 clinical trial in the US on deformed knee joint disease....Good results suggesting validity in the main evaluation items were obtained. In terms of safety, there were no side effects that could be a development problem....Hisamitsu said it plans to begin phase III clinical trials next year."

New P3 trial • P2 data